free bootstrap theme

New topics

Publication

  1. Novel Anti-Obesity Properties of Palmaria mollis in Zebrafish and Mouse Models - Nakayama H, Shimada Y*, Zang L, Terasawa M, Nishiura K, Matsuda K, Toombs C, Langdon C, Nishimura N. Nutrients. 2018;10:1401.
  2. Zebrafish as a Model for Obesity and Diabetes - Zang L, Maddison LA, Chen W. Front Cell Dev Biol., 2018;6:91.
  3. Lipidomic Profiling on Oxidized Phospholipids in Type 2 Diabetes Mellitus Model Zebrafish. - Chen Z, Wu Y, Zang L, Shimada Y, Nakayama H, Rojeet S, Zhao Y, Miura Y, Nishimura N, Chiba H, Hui S. Anal Sci. 2018;34:1201-1208.
  4. 悪性腫瘍モデルゼブラフィッシュを利用した創薬研究 - 島田康人. 生体の科学、2018年、69巻、4号、p365-379.
  5. Performing DNA Nanotechnology Operations on a Zebrafish - Yang J, Meng Z, Liu Q, Shimada Y, Olsthoorn RC, Spaink HP, Herrmann A, Kros A. Chem Sci. 2018;9:7271-7276.
  6. A Novel Live Feed for Rearing First-Feeding Larvae - akayama H, Katayama K, Onabe Y, Sato A, Nishimura N, Shimada Y. Zebrafish. 2018;15:291-294.
  7. Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus - Zang L, Shimada Y, Nishimura N. Sci Rep. 2017;7:1461.
  8. Potential protective function of the sterol regulatory element binding factor 1–fatty acid desaturase 1/2 axis in early-stage age-related macular degeneration.- Ashikawa Y, Nishimura Y, Okabe S, Sato Y, Yuge M, Tada T, Miyao H, Murakami S, Kawaguchi K, Sasagawa S, Shimada Y, Tanaka T*. Heliyon. 2017;3:3.
  9. Application of Coiled Coil Peptides in Liposomal Anti-Cancer Drug Delivery Using a Zebrafish Xenograft Model. - Yang J, Shimada Y*, Olsthoorn RC, Snaar-Jagalska BE, Spaink HP, Kros A*. ACS Nano. 2016;10:7428-7435. 
  10. Comparative study of the zebrafish embryonic toxicity test and mouse embryonic stem cell test to screen developmental toxicity of human pharmaceutical drugs. - Inoue A, Nishimura Y, Matsumoto N, Umemoto N, Shimada Y, Maruyama T, Kayasuga K, Morihara M, Katagi J, Shiroya T, Hirota Y, Kim S, Tanaka T*. Fundam. Toxicol. Sci. 2016;3:79-87. 
  11. Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish. - Zhang B, Shimada Y, Hirota T, Ariyoshi M, Kuroyanagi J, Nishimura Y, Tanaka T*. Transl Res. 2016;170:89-98.
  12. Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity. - Nishimura Y, Sasagwa S, Ariyoshi M, Ichikawa S, Shimada Y, Kawaguchi K, Kawase R, Yamamoto R, Uehara T, Yanai T, Takata R, Tanaka T.* Front Phamacol. 2015;6:19.
  13. Repeated Blood Collection for Blood Tests in Adult Zebrafish. - Zang L*, Shimada Y, Nishimura Y, Tanaka T, Nishimura N.  J. Vis. Exp. 2015;102:e53272.
  14. Rhamnan sulphate from Monostroma nitidum attenuates hepatic steatosis by suppressing lipogenesis in a diet-induced obesity zebrafish model. - Zang L*, Shimada Y, Tanaka T and Nishimura Y.  J Funct Foods. 2015;17:364-370.
  15. E2F8 promotes hepatic steatosis through FABP3 expression in diet-induced obesity in zebrafish. - Shimada Y, Kuninaga S, Ariyoshi M, Zhang B, Shiina Y, Takahashi Y, Umemoto N, Nishimura Y, Enari H and Tanaka T*.  Nutr Metab. 2015;12:17.
  16. In vivo selective imaging and inhibition of leukemia stem-like cells using the fluorescent carbocyanine derivative, DiOC5(3). - Zhang B, Shimada Y*, Kuroyanagi J, Ariyoshi M, Nomoto T, Shintou T, Umemoto N, Nishimura Y, Miyazaki T, Tanaka T*.  Biomaterials. 2015;52:14-25
  17. Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. - Kawabata M, Umemoto N, Shimada Y, Nishimura Y, Zhang B, Kuroyanagi J, Miyabe M, Tanaka T*.  Toxicol Sci. 2015;143:374-384.
  18. Copper Oxide Nanoparticles Reduce Vasculogenesis in Transgenic Zebrafish Through Down-Regulation of Vascular Endothelial Growth Factor Expression and Induction of Apoptosis.  - Chang J, Ichihara G, Shimada Y, Tada-Oikawa S, Kuroyanagi J, Zhang B, Suzuki Y, Sehsah R, Kato M, Tanaka T, Ichihara S*. J Nanosci Nanotechnol. 2015;15:2140-2147. 
Address

2-174 Edobashi, Tsu, Mie, 5148572, Japan

Contacts

Yasuhito Shimada, MD, PhD.
Email: shimada.yasuhito@mie-u.ac.jp                     
Phone: +81 (0) 59 231 5384